Orekhov A N, Baldenkov G N, Tertov V V, Ryong L H, Kozlov S G, Lyakishev A A, Tkachuk V A, Smirnov V N
U.S.S.R. Cardiology Research Center, Moscow.
J Cardiovasc Pharmacol. 1988;12 Suppl 6:S66-8.
Primary cell culture derived from atherosclerotic plaque of human aorta was used to assess direct effects of calcium antagonists, beta-blockers, and nitrates on vessel wall cells. Within 24 h, calcium antagonists (verapamil, nifedipine, darodipine, isradipine, diltiazem, etc.) reduced the cholesterol level in cultured cells. Furthermore, these agents decreased the incorporation of [3H]thymidine. Thus, the calcium antagonists manifested direct antiatherosclerotic action in culture by normalizing major manifestations of atherosclerosis at the cellular level. On the other hand, beta-blockers (propranolol, alprenolol, metoprolol, atenolol, pindolol, and timolol) caused a 1.5- to twofold rise in cholesterol level of cultured cells and stimulated their proliferation. Nitrates (nitroglycerin, isosorbide dinitrate, and nitroprusside) had no effect on atherosclerotic characteristics. Within 2-4 h after a single dose of oral administration of beta-blocker (propranolol), patients' blood plasma turned atherogenic, i.e., its addition to culture-induced cholesterol accumulation and stimulated proliferation. At the same time, blood plasma of patients who received calcium antagonists (verapamil and nifedipine) acquired antiatherosclerotic properties manifested in its ability to lower the intracellular cholesterol level and inhibit proliferative activity of cultured cells. These findings allow the assumption that not only in vitro, but in vivo as well, calcium antagonists and beta-blockers are antiatherosclerotic and atherogenic drugs, respectively.
用人主动脉粥样硬化斑块来源的原代细胞培养物来评估钙拮抗剂、β受体阻滞剂和硝酸盐对血管壁细胞的直接作用。在24小时内,钙拮抗剂(维拉帕米、硝苯地平、达罗地平、伊拉地平、地尔硫䓬等)降低了培养细胞中的胆固醇水平。此外,这些药物减少了[3H]胸腺嘧啶核苷的掺入。因此,钙拮抗剂通过在细胞水平上使动脉粥样硬化的主要表现正常化,在培养中表现出直接的抗动脉粥样硬化作用。另一方面,β受体阻滞剂(普萘洛尔、阿普洛尔、美托洛尔、阿替洛尔、吲哚洛尔和噻吗洛尔)使培养细胞的胆固醇水平升高了1.5至两倍,并刺激了它们的增殖。硝酸盐(硝酸甘油、二硝酸异山梨酯和硝普钠)对动脉粥样硬化特征没有影响。在单次口服β受体阻滞剂(普萘洛尔)后2至4小时内,患者的血浆变得具有致动脉粥样硬化性,即其添加到培养物中会导致胆固醇积累并刺激增殖。同时,接受钙拮抗剂(维拉帕米和硝苯地平)的患者血浆获得了抗动脉粥样硬化特性,表现为能够降低细胞内胆固醇水平并抑制培养细胞的增殖活性。这些发现使得可以假设,不仅在体外,而且在体内,钙拮抗剂和β受体阻滞剂分别是抗动脉粥样硬化药物和致动脉粥样硬化药物。